✦ LIBER ✦

Pegfilgrastim cost effective in recurrent ovarian cancer

Book ID: 125387292
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2014
Weight: 199 KB
Volume: 700
Category: Article
ISSN: 1173-5503
DOI: 10.1007/s40274-014-1175-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab not cost effective in ovaria

Bevacizumab not cost effective in ovarian cancer

✍ Lancsar, Emily; Swait, Joffre 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Paclitaxel + cisplatin cost-effective op

Paclitaxel + cisplatin cost-effective option in ovarian cancer

✍ Langsdale, Tracey 📂 Article 📅 1997 🏛 Adis International Limited (now part of Wolters Kl ⚖ 173 KB

Bevacizumab not cost effective in advanc

Bevacizumab not cost effective in advanced ovarian cancer

✍ Naik, Haladhara; Goswami, Ashok; Kim, Guinyun; Kim, Kwangsoo; Yang, Sung-Chul; S 📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

Management of platinum-sensitive recurre

Management of platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

✍ Laura J. Havrilesky; Angeles Alvarez Secord; Shalini Kulasingam; Evan Myers 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 389 KB

Cost-effectiveness studies in ovarian ca

Cost-effectiveness studies in ovarian cancer

✍ T. D. Szucs; P. Wyss; K. J. Dedes 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Cost-effectiveness of early palliative c

Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer

✍ Lowery, William J.; Lowery, Ashlei W.; Barnett, Jason C.; Lopez-Acevedo, Micael; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 285 KB